Synthesis, characterization and anticonvulsant activity of substituted 4- chloro-2-(4-piperazin-1-YL) quinazolines

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue 5, 2014, Pages 567-571

  Mukherjee, Debkiron ^a   Mukhopadhyay, A ^a   Bhat, K Shridhara ^b   Shridhara, A M ^b   Rao, K S ^b  

^a JADAVPUR UNIVERSITY   (India)

^b Alkem Laboratories Limited   (India)

Author keywords

Anticonvulsant activity; Characterization; Piperazines; Quinazolines; Synthesis

Indexed keywords

2 [4 (1, 2 BENZOISOTHIAZOL 3 YL) PIPERAZIN 1 YL] 4 CHLOROQUINAZOLINE; 2 [4 (4 CHLOROQUINAZOLIN 2 YL) PIPERAZIN 1 YL] ETHANOL; 2 [4 (4 CHLOROQUINAZOLIN 2 YL) PIPERAZIN 1 YL] PHENOL; 2 [[4 (4 CHLOROQUINAZOLIN 2 YL) PIPERAZIN 1 YL] METHOXY] ETHANOL; 4 CHLORO 2 (4 (4 CHLOROQUINAZOLIN 2 YL) PIPERAZIN 1 YL) QUINAZOLINE; 4 CHLORO 2 (4 METHYLPIPERAZIN 1 YL) QUINAZOLINE; 4 CHLORO 2 (4 PIPERAZIN 1 YL) QUINAZOLINE; 4 CHLORO 2 [4 (2, 3 DICHLOROPHENYL) PIPERAZIN 1 YL] QUINAZOLINE; QUINAZOLINE DERIVATIVE; RUFINAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CLONUS; CONTROLLED STUDY; DRUG SYNTHESIS; INFRARED SPECTROPHOTOMETRY; LATENT PERIOD; LD 50; MALE; MORTALITY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SEIZURE;

EID: 84901925543     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Selvam TP and Kumar PV. Quinazoline Marketed drugs - A Review. Research in Pharmacy 2011; 1(1): 1-21.
2. Abbas SE. Synthesis of Some Novel 2,3-Disubstituted-3,4- dihydro-4-quinazolinones as Potential Anticonvulsant Agents. Bull. Fac. Pharm. Cairo Univ. 2007; 45: 119-129.
3. Kacker IK and Zaheer SH. Potential Analgesics Part I. Synthesis of Substituted 4-quinazolones. J. Ind. Chem. Soc. 1951; 28: 344-346.
4. Angelos SA and Meyers JA. The Isolation and Identification of Precursors and Reaction Products in the Clandestine Manufacture of Methaqualone and Mecloqualone. J. Forensic Sci. 1985; 30: 1022-1047.
5. Ager R, Harrison DR, Kennwell PD and Taylor JB. Synthesis and Central Nervous System Activity of Quinazolones Related to 2- Methyl- 3-(o- tolyl) -4 (3H) - quinazolone (Methaqualone). J. Med. Chem. 1977; 20: 379-386.
6. Wolfe JF, Rathman TL, Sleevi MC, Campbell JA and Grenn Wood TD. Synthesis and Anticonvulsant Activity of Some New 2- Substituted 3-aryl-4(3H)-quinazolinones. J. Med. Chem. 1990; 33: 161-166.
7. Gyoten M, Nagaya H, Fukuda S, Ashida Y and Kawano Y. Synthesis of Eosinophil Infiltration Inhibitors with Antihistaminic Activity. Chem. Pharm. Bull. Tokyo 2003; 51(2): 122-133.
8. Magid AG, John A, Moyer Susan TN, Michael W and Usha P. New Antihistamines: Substituted Piperazine and Piperidine Derivatives as Novel H1-Antagonists J. Med. Chem. 1995; 38: 4026-4032.
9. Chaudhary P, Kumar R, Verma AK and Singh D. Synthesis and antimicrobial activity of N-alkyl and N-aryl piperazine derivatives. Bioorg. Med. Chem. 2006; 14: 1819-1826.
10. Hachiro S, Hiroo O, Yasuo A, Youichi I and Yoshiharu Y. Synthesis and Antimicrobial Activity of Amino Acids Conjugated Diphenyl methylpiperazine Derivatives. Japanese J. Pharmacol. 2002; 89(1): 7-20.
11. Rebecca DP and Patricia M. Combinatorial Chemistry & High Throughput Screenings, 1, 4-Bis(3-Aminopropyl) Piperazine Libraries: From the Discovery of Classical Chloroquine-Like Antimalarials to the Identification of New Targets, 2005; 8: 39-48.
12. Makoto K, Tomoko M, Koji Y, Masaki M, Nobuo K, Nobuyuki K, Kenichi K, Masato I, Yuji K, Katsuji O and Takayuki N. Novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter. Bioorg. & Med. Chem. 2003; 11: 3953-3963.
13. Makoto K, Tomoko M, Koji Y, Masaki M, Nobuo K, Nobuyuki K, Kenichi K, Masato I, Yuji K, Katsuji O and Takayuki N. Efficient asymmetric syntheses, determination of absolute configurations and biological activities of 1-[4,4-bis(4- fluorophenyl)butyl]-4-[2-hydroxy-3- (phenylamino)propyl]piperazine as a novel potent dopamine uptake inhibitor in the central nervous system. Bioorg. & Med. Chem. 2004; 12: 3069-3078.
14. He Zhao, Xiaoshu He, Andrew T, Diane H, Andrzej K, Robbin B, Renee P and Jan WF. Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 2: Asymmetric synthesis and biological evaluation. Bioorg. & Med. Chem. Lett. 2002; 12: 3111-3115.
15. Brian D, Jessica P, Teresa P, Lee C, Brian M, Robin S, Julia H, Tracy B, Mary C, John S and Val G. Aryl piperazine melanocortin MC4 receptor agonists. Bioorg. & Med. Chem. Lett. 2003; 13: 3793-3796.
16. Rossen K, Steven AW, Sager J, Reamer RA, Askin D, Volante RP and Reider PJ. Asymmetric hydrogenation of tetrahydro pyrazines: Synthesis of (S)-piperazine-2-tertbutylcarboxamide, an intermediate in the preparation of the HIV protease inhibitor indinavir. Tetrahedron Lett. 1995; 36: 6419-6422.
17. David A, Kan KE, Kai R, Robert MP, Kenneth MW, Volante RP and Paul JR. Highly diastereo selective reaction of a chiral, nonracemic amide enolate with (S)-glycidyl tosylate. Synthesis of the orally active HIV-1 protease inhibitor L-735,524, Tetrahedron Lett. 1994; 35(5): 673-676.
18. Marona H, Korona R and Szneler E. Boll. Chim. Farmac. 2004; 143: 329.
19. Lorke DA. A New Approach to practical acute toxicity testing. Arch. Toxicol. 1983; 54: 275-287.
20. Swinyard EA, Woodhead JH, White HS and Franklin MR. General Principle; Experimental, Selection Quantification and Evaluation of Anticonvulsants. In: Antiepileptic Drugs. Levy RH, Mattson RH, Melrum B, Penry JK, Dreifuss H. (eds). Raven press, New York, 1989; Pp. 85-102.
21. Shashiprabha, Kanakamajalu S, Debkiron M, Padmashree B, Ksundarraja R and Kuppuswamy N. Process for the preparation of Ziprasidone. U.S.Pat.No. 8,410,268B2. 2013.
22. Raza M, Farzane S, Choudhary MI, Amin S. Attaur-Rahman S, Sompong S and De-lorenzo RJ. Phytother. Res. 2001; 15: 426-430.